PPCB ▲ +2.0% - Propanc Biopharma, Inc. $PPCB - Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib 07-OCT-2026 08:31 AM ET